| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 750 | 720 | 1,560 | 0 | 40 |
| Sales Growth | +4.17% | -53.85% | unch | -100.00% | -85.19% |
| Net Income | -61,070 | -27,730 | -26,430 | -38,960 | -26,290 |
| Net Income Growth | -120.23% | -4.92% | +32.16% | -48.19% | +54.13% |
Atai Beckley N.V. (ATAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
AtaiBeckley N.V. is a clinical-stage biopharmaceutical company which focused on mental health treatments. AtaiBeckley N.V., formerly known as atai Life Sciences, is based in NEW YORK.
Fiscal Year End Date: 12/31